ORIGINAL PAPER

Clinical Presentation of Extraintestinal Infections Caused by Non-typhoid Salmonella Serotypes Among Patients at the University Hospital in Cracow During an 7-year Period

JOLANTA KĘDZIERSKA¹, BEATA PIĄTKOWSKA-JAKUBAS², ANNA KĘDZIERSKA^{1,3*}, GRAŻYNA BIESIADA⁴, ANDRZEJ BRZYCHCZY⁵, AGNIESZKA PARNICKA⁶, BEATA MIĘKINIA⁷, ALDONA KUBISZ⁸ and WŁADYSŁAW SUŁOWICZ⁹

¹ Department of Microbiology, University Hospital, Cracow, Poland
² Department of Hematology, ³Department of Clinical Microbiology, Polish-American Institute of Pediatrics
⁴ Department of Gastroenterology and Hepatology, Division of Infectious Diseases
⁵ 2nd Chair of Surgery, ⁶ Department of Internal Diseases and Gerontology
⁷ Department of Allergy, Immunology and Pulmonology, ⁸ Department of Surgery and Gastroenterology
⁹ Department of Nephrology, Jagiellonian University Medical College, Cracow, Poland

Received 9 October 2007, revised 10 January 2008, accepted 11 January 2008

Abstract

The most characteristic finding in non-typhoid salmonella (NTS) infection is acute food related outbreaks of gastroenteritis, which is usually benign and self-limiting. However, more serious extraintestinal findings, such as bacteraemia and focal infections localized to any organ may appear. The objective of this paper is to describe the most important characteristic of the extraintestinal infections due to NTS serotypes observed in University Hospital, in Cracow between January 2000 and December 2006. To do so, we reviewed the clinical presentations, risk groups, complications and outcomes of in-patients, in which extraintestinal non-typhoid *Salmonella* serotypes were isolated, applying a clinomicrobiological protocol. Out of 30 patients with either bacteraemias (n = 22) or focal salmonella infections (n = 8), 12 had malignancies, 17 had immune dysfunction state, 9 had gastrointestinal disorders and 8 had chronic heart, pulmonary or kidney disease. Four of these patients (13%) who had hematological malignancies (2), renal transplantation (1) and pulmonary disease (1) died. Regarding the clinical picture, primary bacteraemia and focal infections occurred with similar frequency (33.3% and 26.7%, respectively); the remaining were bacteraemias secondary to gastroenteritis. The incidence rate (mean 0.30/1000 hospital admission/year) increased steadily from 0.19/1000 to 0.32/1000 hospital admission during the study period. From 30 *Salmonella* isolates from extraintestinal samples collected, only four isolates were resistant to ampicillin, ciprofloxacin or trimethoprim-sulfamethoxazole. This finding indicate that multidrug resistance does not represent a serious problem among NTS serotypes collected from the our medical center as monitored over a period of 7 years. Given this presentation, clinicians need to have a high index of suspicion and to consider preemptive therapy, especially in elderly patients who are likely to develop severe immunosuppression following interventions.

K e y w o r d s: Salmonella serotypes, salmonella infections, risk factors, bacteraemia, immunosuppression

Introduction

Salmonella spp. are Gram-negative, facultative anaerobic, motile, non-lactose-fermenting, non-sporeforming bacilli. All Salmonella serotypes share the ability to invade the host by inducing their own uptake into cells of the intestinal epithelium and establishing systemic infection through their ability to survive and replicate in mononuclear phagocytes (Ohl and Miller, 2001). Recent years have seen a dramatic rise in the incidence and severity of cases of human salmonellosis (Gradel *et al.*, 2006; Jean *et al.*, 2006). Nontyphoid salmonella is widely dispersed in nature, and presents as sporadic food related outbreaks of gastroenteritis with or without extraintestinal manifestations, especially in immunocompromised patients (Glaser *et al.*, 1985; Pagano *et al.*, 1997; Hohmann, 2001). These manifestations are varied and if unrecognized can be important causes of morbidity and mortality (Gordon *et al.*, 2001; Habib, 2004). Extraintestinal non-typhoid salmonella infections make up 1.8% of all salmonellosis and most of them occur in childhood or in the elderly (Ruiz *et al.*, 2000).

Host conditions associated with increased risk of salmonellosis include gastric hypoacidity, extremes of age, alteration of the endogenous bowel flora,

^{*} Corresponding author: A. Kędzierska, Department of Clinical Microbiology, Polish-American Institute of Pediatrics, Jagiellonian University Medical College, Wielicka 265, 30-663 Cracow, Poland; phone: (48) 12 6582011 ex. 1328; e-mail: mmkedzie@cyf-kr.edu.pl

malignancy, diabetes mellitus, rheumatological disorders, reticuloendothelial blockade (sickle cell disease, malaria or bartonellosis), and therapeutic immunosuppression (Hsu *et al.*, 2003; Hsu and Lin, 2005). In certain conditions, non-typhoid salmonella can get into the bloodstream, and cause bacteraemia or localized infections in different organ systems (Pagano *et al.*, 1997; Day *et al.*, 2002; Habib, 2004; Gönen *et al.*, 2004; Minami *et al.*, 2004; Gagnon *et al.*, 2007). Therefore it is important to identify high-risk patients and treat them as early as possible.

The aim of our study was to determine the incidence of salmonella infections with extraintestinal manifestations among patients hospitalized at the University Hospital in Cracow during 2000–2006. Here we report a clinical audit of salmonella septicaemic patients seen over a 7-year period in order to describe the risk groups, complications and hospital outcome of non-typhoid salmonella infections. Moreover, we assessed the antimicrobial susceptibility profile of *Salmonella* clinical isolates collected from patients with extraintestinal infections seen during the study period. The present analysis confirmed the work of others that the greatest risk of acquiring focal infections is associated with the existence of underlying illness or immunodepression.

Experimental

Materials and Methods

Patients. Patients were recruited from a retrospective analysis of the clinical, and bacteriological data for adult patients with non-typhoid salmonella from January 2000 through December 2006. Patients were included if they had at least one culture positive for NTS. A total of thirty patients with extraintestinal manifestations of salmonella infections were included in the study. The isolates of *Salmonella* were recovered from specimens collected from: (a) venous blood (VB; n = 21); (b) blood from central venous catheter (CVC; n = 1); (c) urine (U; n = 4); (d) pus (P; n = 3), and (e) bronchial washings (BW; n = 1).

Data collection. Details for all patients whose blood cultures tested positive for *Salmonella* were drawn from the our Department of Microbiology, and medical records of University Hospital in Cracow, in the study period. Clinical and laboratory data were obtained from patient's records and analyzed retrospectively. The medical records of patients with NTS salmonellosis were reviewed, and data were recorded for demographic (age and gender), underlying medical diseases (diabetes mellitus, liver cirrhosis, systemic lupus erythematosus, hypertension, pneumonia, bronchitis, previous isochaemic stroke, chronic obstructive pulmonary disease, organ abscesses, human immunodeficiency virus infection, hematological malignancy or solid organ malignancy), bacteriology (Serogroups A, B, C, D, E, G and H) and hospital outcome (death). We defined immunodeficiency as having acquired human immunodeficiency virus (HIV) infection, use of corticosteroid and chemotherapeutic agents for malignancy or autoimmune diseases, or use of immunosuppressive agents for organ transplantation (Hsu *et al.*, 2003).

Qualitative evaluation of bacteria. The study material was based on taking venous blood samples (95.2%), and from CVC (4.8%). Microbiological blood examination were performed in constant monitoring system of collected specimens. Automatic BacT/Alert (bioMerieux) system was used, what allowed for early bacterial blood samples identification. For aerobic bacteria cultures standard media was used - BacT/AlertTM SA Culture Bottle, and BacT/AlertTM FA Culture Bottle. Additionally, all tested samples were placed directly onto nonselective Columbia agar plates supplemented with 5% of blood sheep, and onto selective McConkey'a agar plates (bioMerieux). Stool samples, and rectum swabs were placed additionally onto selective routine media Wilson-Blair (Difco), Salmonella-Shigella (Difco), and selenito F (Difco). The plates were then incubated at 37°C for 18-24 h, and the colonies suspected for salmonella bacilli were isolated. Isolates of Salmonella were initially identified by biochemical tests. Additionally, cultured microorganisms were identified with usage of commercial ID 32E system (bioMerieux) for Enterobacteriaceae family according to the manufacture's guidelines. Serogruping was determined by agglutination testing with use of antisera specific to O antigen: AO, BO, CO, DO, and EO (Biomed, Cracow). All Salmonella isolates, excluding Salmonella enterica subsp. enterica serovar Enteritidis (S. Enteritidis), were further sent to Reference Laboratory in Cracow for serological types confirmation.

Antibiotic susceptibility testing. The agar discdiffusion method was performed according to Clinical and Laboratory Standards Institute (CLSI/NCCLS - National Committee for Clinical Laboratory Standards (NCCLS, 2003a; CLSI, 2007). Single colonies were selected and suspended in sterile 0.9% NaCl solution to prepare the inoculum. Bacterial suspension was inoculated with a sterile swab dipped into the inoculum adjusted to the density 0.5 McFarland turbidity standard. Inoculated Mueller-Hinton agar plates (bioMerieux) were left to dry before application of antibiotic discs. The plates were then inverted and incubated at 35°C for 16-18 h. Analysis was also conducted with the use of antibiogram cards VITEK and VITEK[®]2 compact (bioMerieux) for Gram-negative rods. The tests are in the form of small, waterproof cards with 64 wells containing antibacterial drugs (antibiogram tests) in different dilutions suitable for testing microorganism according to the CLSI recommendations. Tests were performed according to the manufacture's instruction. The following antimicrobials were included in the study: ampicillin (10 μ g), cefotaxime (30 μ g), ceftazidime (30 μ g), ciprofloxacin (5 μ g), and trimethoprim-sulfamethoxazole (1.25/23.75 μ g). The antibiotic discs were obtained from Oxoid.

ESBL detection. Extended-spectrum β -lactamase activity was detected in *Salmonella* isolates by the double disc synergy (DDS) test (Jarlier *et al.*, 1988) with discs containing cefotaxime, ceftazidime and amoxicillin/clavulanate.

Results

Over a seven-year period (2000–2006), 438 isolates belonging to Salmonella were isolated from clinical samples of patients (n = 9.418) of University Hospital in Cracow. Among them, there were 405 intestinal salmonella infections (92.5%), 22 bloodstream infections (5.0%), and 8 extraintestinal non-bacteraemic infections (1.8%). Of the 438 Salmonella isolates only three (0.7%) were Salmonella enterica subsp. enterica serovar Paratyphi A (n = 2) and S. Paratyphi B (n = 1), while 99.3% were non-typhoid salmonella. The distribution of all Salmonella serotypes is shown in the Table I. The annual number of NTS infection episodes ranged from 62 in 2000 to 35 in 2006 (data not shown). The most frequently isolated was the serotype Salmonella enterica subsp. enterica serovar Enteritidis (S. Enteritidis; 86.7% of cases), and after that Salmonella enterica subsp. enterica serovar Hadar (S. Hadar; 6.7% of cases). Majority of these NTS isolates were

Table I The distribution of *Salmonella* serotypes isolated from patients hospitalized at the University Hospital in Cracow during a 7-year study period

Serological type serovar	Sero- groups	No. (%) of isolates from stool samples	No. (%) of isolates from other samples ^{a)}
S. Enteritidis	D ₁ 330 (81.3)		26 (86.7)
S. Hadar	C ₂	19 (4.7)	2 (6.7)
S. Virchow	C ₁	18 (4.4)	—
S. Typhimurium	В	13 (3.2)	—
S. Infantis	C ₁	10 (2.5)	1 (3.3)
S. Indiana	В	5 (1.2)	_
S. Bareilly	C ₁	2 (0.5)	—
S. Braenderup	C ₁	2 (0.5)	1 (3.3)
S. Agona	В	1 (0.2)	-
S. Anatum	E ₁	1 (0.2)	—
S. Bovismorbificans	C ₂	1 (0.2)	_
S. Hlingdon	D ₂	1 (0.2)	—
S. Mbandaka	C ₁	1 (0.2)	_
S. Newport	C ₂	1 (0.2)	_
Total		n = 405	n = 30

 a) Including venous blood, urine, pus, central venous catheter, and bronchial washings samples

obtained from Department of Gastroenterology and Hepatology and Infectious Diseases (36.7%) and Department of Hematology (26.7%). The annual case number and incidence (cases per 1000 discharges) of adult patients with extraintestinal manifestations during each year is illustrated in Fig. 1. Blood samples yielded most of the NTS isolates (73.3%), followed by urine samples (13.3%), pus samples (10%), and




Fig. 1. Incidence and number of patients with extraintestinal salmonella manifestations treated at the University Hospital in Cracow from 2000 to 2006.

Kędzierska J. et al.

Table II
Non-typhoid salmonella infections during the period $2000-2006$ (n = 30)

Gender Isolate/Source of day(s)* stool sample Clinical dagnosis Clinical cases with bloodstream infections (n = 22) 70/F S. Enteritidis/VB 5 days + septicaemia 2 70/F S. Enteritidis/VB 1 day - myeloma 3 31/F S. Enteritidis/VB 11 days - chronic lymphatic leukaemia 5 30/F S. Enteritidis/VB 11 days - chronic lymphatic leukaemia 6 59/M S. Enteritidis/VB 11 days - chronic lymphatic leukaemia 6 59/M S. Enteritidis/VB 11 day + asure gatternetrocolitis 7 60/M S. Enteritidis/VB at admission - septicaemia; renal transplantation 8 31/M S. Enteritidis/VB M day + septicaemia; transplantation 10 74/F S. Enteritidis/VB 1 day + septicaemia; COPD; circulatory and respiratory failure; isochaemic heart diseas 12 38/M S. Enteritidis/VB 1 day <td< th=""><th></th><th></th><th></th><th></th><th></th><th></th></td<>						
Clinical cases with bloodstream infections (n = 22)176/FS. Enteritidis/VB5 days+septicaemia270/FS. Enteritidis/VB1 day-myeloma331/FS. Enteritidis/VB1 days-chronic lymphatic leukaemia530/FS. Enteritidis/VB1 l days+acute gastrenterocollitis659/MS. Enteritidis/VB1 l days+acute gastrenterocollitis660/MS. Enteritidis/VBat admission-septicaemia; renal failure; COPD; arterial hypertension; epilepsy760/MS. Enteritidis/VBat admission-septicaemia; renal transplantation831/MS. Enteritidis/VBat admission-septicaemia; renal transplantation774/FS. Enteritidis/VB4 days+gesticaemia; bronchitic asthma; cholecystolithiasis; virus hepatitis;1139/MS. Enteritidis/VB1 day+septicaemia; DM1238/MS. Enteritidis/VB1 day+geroteamia1380/MS. Enteritidis/VB1 day+septicaemia; DM1433/FS. Enteritidis/VB1 day-non-Hodgkin lymphoma DLBCL1556/MS. Enteritidis/VB1 day-non-Hodgkin lymphoma DLBCL1640/FS. Enteritidis/VB1 day-septicaemia1731/FS. Hadar/VB1 day-septicaemia1864/MS. Enteritidis/VB	Case	Age/	NTS Jaclata/Sauraa	No. $af day(a)^{a}$	Isolation from	Clinical diagnosis
176/FS. Enteritidis/VB5 days+septicaemia270/FS. Enteritidis/VB1 day-myeloma331/FS. Enteritidis/VB1 days-chronic lymphatic leukaemia530/FS. Enteritidis/VB11 days+acute gastrenterocolitis659/MS. Enteritidis/VB11 days+acute gastrenterocolitis760/MS. Enteritidis/VBat admission-septicaemia; renal failure; COPD; arterial hypertension; epilepsy760/MS. Enteritidis/VBat admission+salmonellosis831/MS. Enteritidis/VB4 days+posthepatitic cirrhosis; virus hepatitis C1074/FS. Enteritidis/VB25 days-aplastic aermia1139/MS. Enteritidis/VB1 day+septicaemia; fecal vomiting1139/MS. Enteritidis/VB1 day+septicaemia; OCPD; circulatory and respiratory failure; isochaemic heart disease1433/FS. Enteritidis/VB5 days+multiple myeloma; gastenterocolitis; renal failure1556/MS. Enteritidis/VB1 day-non-Hodgkin lymphoma DLBCL1640/FS. Enteritidis/VB1 day-septicaemia1731/FS. Interitidis/VB1 day-acute myelobastic leukemia1864/MS. Enteritidis/VB1 day-non-Hodgkin lymphoma DLBCL1970/FS. Hadar/VB1 day-		Gendel Isolate/Source of day(s) / stool sample				
270/FS. Enteritidis/VB1 day-myeloma331/FS. Enteritidis/VB11 days+fod poisoning462/MS. Enteritidis/VB11 days+acute gastrenterocolitis530/FS. Enteritidis/VB11 days+acute gastrenterocolitis659/MS. Enteritidis/VB11 days+acute gastrenterocolitis760/MS. Enteritidis/VBat damission-septicaemia; renal transplantation831/MS. Enteritidis/VBat admission+salmonellosis972/MS. Enteritidis/VB4 days+posthepatitic cirrhosis; virus hepatitis C1074/FS. Enteritidis/VB1 day+septicaemia; bronchitic asthma; cholecystolithiasis; virus hepatitis; nausea; diarrhea; fecal vomiting1139/MS. Enteritidis/VB1 day+prostatic carcinoma; COPD; circulatory and respiratory failure; isochaemic heart disease1238/MS. Enteritidis/VB1 day+multiple myeloma; gastrenterocolitis; renal failure1556/MS. Enteritidis/VB1 day-non-Hodgkin lymphoma DLBCL1640/FS. Enteritidis/VB1 day-septicaemia1970/FS. Hadar/VB4 days+fod poisoning; cancer of the breast2046/FS. Enteritidis/VB1 day-septicaemia; HV infection2130/FS. Enteritidis/VBND-septicaemia; MIV infection22 <td>1</td> <td colspan="5"></td>	1					
3 $31/F$ S. Enteritidis/ VB $2 days$ +fod poisoning4 $62/M$ S. Enteritidis/ VB11 days-chronic lymphatic leukaemia5 $30/F$ S. Enteritidis/ VB11 days+acute gastrenterocolitis6 $59/M$ S. Enteritidis/ VB1 day+aslmoollosis, septicaemia; renal failure; COPD; arterial hypertension; epilepsy7 $60/M$ S. Enteritidis/ VBat admission-septicaemia; renal transplantation9 $72/M$ S. Enteritidis/ VBat admission+salmoollosis9 $72/M$ S. Enteritidis/ VB4 days+septicaemia; bronchitic asthma; cholecystolithiasis; virus hepatitis; nausa; diarrhea; fecal vomiting11 $39/M$ S. Enteritidis/ VB1 day+septicaemia; DM12 $38/M$ S. Enteritidis/ VB1 day+septicaemia; DM13 $80/M$ S. Enteritidis/ VB5 days+multiple myeloma; gastrenterocolitis; renal failure14 $33/F$ S. Enteritidis/ VB1 day-non-Hodgkin lymphoma DLBCL15 $56/M$ S. Enteritidis/ VB1 day-non-Hodgkin lymphoma DLBCL16 $40/F$ S. Enteritidis/ VBND+septicaemia17 $31/F$ S. Enteritidis/ VBND+septicaemia18 $64/M$ S. Enteritidis/ VBND+septicaemia19 $70/F$ S. Hadar/ VBND+septicaemia19 $70/F$ S. Hadar/				-		
462/MS. Enteritidis/VB11 dayschronic lymphatic leukaemia530/FS. Enteritidis/VB11 days+acute gastrenterocolitis659/MS. Enteritidis/VB1 day+salmonellosis; septicaemia; renal failure; COPD; arterial hypertension; epilepsy760/MS. Enteritidis/VBat admission-septicaemia; renal transplantation831/MS. Enteritidis/VBat admission+salmonellosis972/MS. Enteritidis/VB4 days+posthepatitic cirrhosis; virus hepatitis C1074/FS. Enteritidis/VB2 days-aplastic anemia1139/MS. Enteritidis/VB1 day+septicaemia; bronchitic asthma; cholecystolithiasis; virus hepatitis; nausea; diarrhea; fecal vomiting1139/MS. Enteritidis/VB1 day+septicaemia; DM1238/MS. Enteritidis/VB1 day+prostatic carcinoma; COPD; circulatory and respiratory failure; isochaemic heart disease1380/MS. Enteritidis/VB1 day-non-Hodgkin lymphoma DLBCL1433/FS. Enteritidis/VB1 day-non-Hodgkin lymphoma DLBCL1556/MS. Enteritidis/VB1 day-septicaemia; tono-Hodgkin lymphoma DLBCL1640/FS. Enteritidis/VB1 day-septicaemia; tono-Hodgkin lymphoma DLBCL1731/FS. Hadar/VB1 day-septicaemia; tono-Hodgkin lymphoma DLBCL18 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
5 $30/F$ S. Enteritidis/ VB11 day+acute gastrenterocolitis6 $59/M$ S. Enteritidis/ VB1 day+salmonellosis; septicaemia; renal failure; COPD; arterial hypertension; epilepsy7 $60/M$ S. Enteritidis/ VBat admission-septicaemia; renal transplantation8 $31/M$ S. Enteritidis/ VBat admission+salmonellosis; posthepatitic cartinosi; virus hepatitis C9 $72/M$ S. Enteritidis/ VBND+posthepatitic cartinosi; rausea; diarrhea; fecal vomiting11 $39/M$ S. Enteritidis/ VB25 days-aplastic anemia12 $38/M$ S. Enteritidis/ VB1 day+septicaemia; ronal transplantation13 $80/M$ S. Enteritidis/ VB1 day+group and respiratory failure; isochaemic heart disease14 $33/F$ S. Enteritidis/ VB5 days-non-Hodgkin lymphoma CTCL16 $40/F$ S. Enteritidis/ VB1 day-non-Hodgkin lymphoma DLBCL17 $31/F$ S. Hadar/ VB1 day-septicaemia19 $70/F$ S. Hadar/ VB1 day-septicaemia20 $46/F$ S. Enteritidis/ VB1 day-septicaemia21 $30/F$ S. Enteritidis/ VB1 day-septicaemia22 $59/F$ S. Enteritidis/ VB1 day-septicaemia23 $23/M$ S. Enteritidis/ VB1 day-septicaemia24 $40/F$						
6 59/M S. Enteritidis/ VB 1 day + salmonellosis; septicaemia; renal failure; COPD; arterial hypertensio; epilepsy 7 60/M S. Enteritidis/ VB at admission - septicaemia; renal transplantation 8 31/M S. Enteritidis/ VB at admission + septicaemia; renal transplantation 9 72/M S. Enteritidis/ VB ND + posthepatitic cirrhosis; virus hepatitis C 10 74/F S. Enteritidis/ VB 4 days + septicaemia; bronchitic asthma; cholecystolithiasis; virus hepatitis; nausea; diarrhea; fecal vomiting 11 39/M S. Enteritidis/ VB 1 day + septicaemia; DM 12 38/M S. Enteritidis/ VB 1 day + septicaemia; DM 13 80/M S. Enteritidis/ VB 5 days + multiple mycloma; gastrenterocolitis; renal failure 15 56/M S. Enteritidis/ VB 1 day - non-Hodgkin lymphoma DLBCL 16 40/F S. Enteritidis/ VB 1 day - non-Hodgkin lymphoma DLBCL 17 31/F S. Hadar/ VB 1 day - Septicaemia						
Image: constraint of the second se						-
831/MS. Enteritidis/ VBat admission+salmonellosis972/MS. Enteritidis/ VBND+posthepatitic cirrhosis; virus hepatitis C1074/FS. Enteritidis/ VB4 days+septicaemia; bronchitic asthma; cholecystolithiasis; virus hepatitis; nausea; diarrhea; fecal vomiting1139/MS. Enteritidis/ VB1 day+septicaemia; DM1238/MS. Enteritidis/ VB1 day+septicaemia; DM1380/MS. Enteritidis/ VB1 day+multiple myeloma; gastrenterocolitis; renal failure1433/FS. Enteritidis/ VB5 days+multiple myeloma; gastrenterocolitis; renal failure1556/MS. Enteritidis/ VB2 days-non-Hodgkin lymphoma DLBCL1640/FS. Enteritidis/ VB1 day-septicaemia1731/FS. Hadar/ VB1 day-septicaemia1970/FS. Enteritidis/ VBND+septicaemia2046/FS. Enteritidis/ VBND-septicaemia2130/FS. Enteritidis/ VBND-septicaemia; HIV infection2259/FS. Enteritidis/ VB1 day-septicaemia; HIV infection2323/MS. Enteritidis/ P1 day-acute suppurative appendicitis; retrocecal abscess; gastroenterocolitis2465/MS. Enteritidis/ P1 day+acute suppurative appendicitis; retrocecal abscess; astroenterocolitis<	6	59/M	S. Enteritidis/ VB	1 day	+	
972/MS. Enteritidis/VBND+posthepatitic cirrhosis; virus hepatitis C1074/FS. Enteritidis/VB4 days+septicaemia; bronchitic asthma; cholecystolithiasis; virus hepatitis; nausea; diarrhea; fecal vomiting1139/MS. Enteritidis/VB25 days-aplastic anemia1238/MS. Enteritidis/VB1 day+septicaemia; DM1380/MS. Enteritidis/VB1 day+prostatic carcinoma; COPD; circulatory and respiratory failure; isochaemic heart disease1433/FS. Enteritidis/VB5 days+multiple myeloma; gastrenterocolitis; renal failure1556/MS. Enteritidis/VB2 days-non-Hodgkin lymphoma DLBCL1640/FS. Enteritidis/VB1 day-non-Hodgkin lymphoma DLBCL1731/FS. Hadar/VB1 day-septicaemia1970/FS. Enteritidis/VB1 day-septicaemia2046/FS. Enteritidis/VB1 day-septicaemia2130/FS. Enteritidis/VBND-septicaemia2259/FS. Enteritidis/VBND-septicaemia; enterior2323/MS. Enteritidis/P1 day-acute myeloblastic leukemia2465/MS. Enteritidis/P1 day+acute suppurativa appendicits; retrocecal abscess; gastroenterocolitis abscess of the splean2465/MS. Enteritidis/P1 day+acute suppurativa append	7	60/M	S. Enteritidis/ VB	at admission	_	septicaemia; renal transplantation
10 $74/F$ S. Enteritidis/ VB4 days+septicaemia; bronchitic asthma; cholecystolithiasis; virus hepatitis; nausea; diarrhea; fecal vomiting11 $39/M$ S. Enteritidis/ VB 25 days-aplastic anemia12 $38/M$ S. Enteritidis/ VB1 day+septicaemia; DM13 $80/M$ S. Enteritidis/ VB1 day+prostatic carcinoma; COPD; circulatory and respiratory failure; isochaemic heart disease14 $33/F$ S. Enteritidis/ VB5 days+multiple mycloma; gastrenterocolitis; renal failure15 $56/M$ S. Enteritidis/ VB2 days-non-Hodgkin lymphoma CTCL16 $40/F$ S. Enteritidis/ VB1 day-non-Hodgkin lymphoma DLBCL17 $31/F$ S. Hadar/ VB1 day-non-Hodgkin lymphoma DLBCL18 $64/M$ S. Enteritidis/ VBND+septicaemia19 $70/F$ S. Hadar/ VB1 day-SLE21 $30/F$ S. Enteritidis/ VBND-septicaemia22 $59/F$ S. Enteritidis/ VBND-septicaemia; HIV infection23 $23/M$ S. Enteritidis/ P1 day-acute mycloblastic leukemia24 $65/M$ S. Enteritidis/ P1 day+acute suppurative appendicitis; retrocecal abscess; gastroenterocolitis24 $65/M$ S. Enteritidis/ P1 day+acute suppurative appendicitis; retrocecal abscess; gastroenterocolitis25 $72/M$ S. Enteritidis/ P </td <td>8</td> <td>31/M</td> <td>S. Enteritidis/ VB</td> <td>at admission</td> <td>+</td> <td>salmonellosis</td>	8	31/M	S. Enteritidis/ VB	at admission	+	salmonellosis
IndicationIndicationnausea; diarrhea; fecal vomiting1139/MS. Enteritidis/ VB25 days-aplastic anemia1238/MS. Enteritidis/ VB1 day+septicaemia; DM1380/MS. Enteritidis/ VB1 day+prostatic carcinoma; COPD; circulatory and respiratory failure; isochaemic heart disease1433/FS. Enteritidis/ VB5 days+multiple myeloma; gastrenterocolitis; renal failure1556/MS. Enteritidis/ VB2 days-non-Hodgkin lymphoma CTCL1640/FS. Enteritidis/ VB1 day-non-Hodgkin lymphoma DLBCL1731/FS. Hadar/ VB1 day-non-Hodgkin lymphoma DLBCL1864/MS. Enteritidis/ VBND+septicaemia2046/FS. Enteritidis/ VBND+septicaemia2130/FS. Enteritidis/ VBND-septicaemia; HIV infection2259/FS. Enteritidis/ VBND-acute myeloblastic leukemia2323/MS. Enteritidis/ P1 day+acute suppurative appendicitis; retroceal abscess; gastroenterocolitis2465/MS. Enteritidis/ P1 day+acute suppurative appendicitis; retroceal abscess; c. Enteritidis2572/MS. Enteritidis/ P1 day+acute suppurative appendicitis; retroceal abscess; c. Enteritidis2572/MS. Enteritidis/ P1 day-septicaemia; DM; myocardial infarction; subphrenic abscess; <br< td=""><td>9</td><td>72/M</td><td>S. Enteritidis/ VB</td><td>ND</td><td>+</td><td>posthepatitic cirrhosis; virus hepatitis C</td></br<>	9	72/M	S. Enteritidis/ VB	ND	+	posthepatitic cirrhosis; virus hepatitis C
1139/MS. Enteritidis/ VB25 days-aplastic anemia1238/MS. Enteritidis/ VB1 day+septicaemia; DM1380/MS. Enteritidis/ VB1 day+prostatic carcinoma; COPD; circulatory and respiratory failure; isochaemic heart disease1433/FS. Enteritidis/ VB5 days+multiple myeloma; gastrenterocolitis; renal failure1556/MS. Enteritidis/ VB2 days-non-Hodgkin lymphoma CTCL1640/FS. Enteritidis/ VB1 day-non-Hodgkin lymphoma DLBCL1731/FS. Hadar/ VB1 day-non-Hodgkin lymphoma DLBCL1864/MS. Enteritidis/ VBND+septicaemia1970/FS. Hadar/ VB1 day-SLE2046/FS. Enteritidis/ VBND-septicaemia; HIV infection2130/FS. Enteritidis/ VB1 day-acute myeloblastic leukemia2259/FS. Enteritidis/ VB1 day-acute myeloblastic leukemia2323/MS. Enteritidis/ P1 day+acute suppurative appendicitis; retroccal abscess; gastroenterocolitis2465/MS. Enteritidis/ Pat admission-thrombocytopenia; subphrenic abscess; (S. Enteritidis2572/MS. Enteritidis/ Pat admission-septicaemia; DM; myocardial infarction; subphrenic abscess; bilateral pneumonia and bronchitis2675/MS. Enteritidis/ BW2 days-	10	74/F	S. Enteritidis/ VB	4 days	+	
13 80/M S. Enteritidis/ VB 1 day + prostatic carcinoma; COPD; circulatory and respiratory failure; isochaemic heart disease 14 33/F S. Enteritidis/ VB 5 days + multiple myeloma; gastrenterocolitis; renal failure 15 56/M S. Enteritidis/ VB 2 days - non-Hodgkin lymphoma CTCL 16 40/F S. Enteritidis/ VB 2 days - non-Hodgkin lymphoma DLBCL 17 31/F S. Hadar/ VB 1 day - non-Hodgkin lymphoma DLBCL 18 64/M S. Enteritidis/ VB 1 day - non-Hodgkin lymphoma DLBCL 19 70/F S. Hadar/ VB 4 days + food poisoning; cancer of the breast 20 46/F S. Enteritidis/ VB ND - septicaemia 12 30/F S. Enteritidis/ VB ND - septicaemia; HIV infection 21 30/F S. Enteritidis/ P 1 day + acute myeloblastic leukemia 22 59/F S. Enteritidis/ P 1 day + acute suppurative appendicits; retroceal abscess; gastroenterocolitis 24 65/M <td>11</td> <td>39/M</td> <td>S. Enteritidis/ VB</td> <td>25 days</td> <td>_</td> <td></td>	11	39/M	S. Enteritidis/ VB	25 days	_	
13 80/M S. Enteritidis/ VB 1 day + prostatic carcinoma; COPD; circulatory and respiratory failure; isochaemic heart disease 14 33/F S. Enteritidis/ VB 5 days + multiple myeloma; gastrenterocolitis; renal failure 15 56/M S. Enteritidis/ VB 2 days - non-Hodgkin lymphoma CTCL 16 40/F S. Enteritidis/ VB 2 days - non-Hodgkin lymphoma DLBCL 17 31/F S. Hadar/ VB 1 day - non-Hodgkin lymphoma DLBCL 18 64/M S. Enteritidis/ VB 1 day - non-Hodgkin lymphoma DLBCL 19 70/F S. Hadar/ VB 4 days + food poisoning; cancer of the breast 20 46/F S. Enteritidis/ VB ND - septicaemia 12 30/F S. Enteritidis/ VB ND - septicaemia; HIV infection 21 30/F S. Enteritidis/ P 1 day + acute myeloblastic leukemia 22 59/F S. Enteritidis/ P 1 day + acute suppurative appendicits; retroceal abscess; gastroenterocolitis 24 65/M <td>12</td> <td>38/M</td> <td>S. Enteritidis/ VB</td> <td></td> <td>+</td> <td>-</td>	12	38/M	S. Enteritidis/ VB		+	-
1556/MS. Enteritidis/ VBat admission-non-Hodgkin lymphoma CTCL1640/FS. Enteritidis/ VB2 days-non-Hodgkin lymphoma DLBCL1731/FS. Hadar/ VB1 day-non-Hodgkin lymphoma DLBCL1864/MS. Enteritidis/ VBND+septicaemia1970/FS. Hadar/ VB4 days+food poisoning; cancer of the breast2046/FS. Enteritidis/ VB1 day-SLE2130/FS. Enteritidis/ VBND-septicaemia; HIV infection2259/FS. Enteritidis/ VBND-acute myeloblastic leukemiaClinical cases with focal infections (n = 8)2323/MS. Enteritidis/ P1 day+acute suppurative appendicitis; retrocecal abscess; gastroenterocolitis2465/MS. Enteritidis/ Pat admission-thrombocytopenia; subphrenic abscess (S. Enteritidis2465/MS. Enteritidis/ Pat admission-septicaemia; DM; myocardial infarction; subphrenic abscess; abscess of the spleen2572/MS. Enteritidis/ Pat admission-reactivity arthritis; septicaemia; coronary atheromatosis; bilateral pneumonia and bronchitis2769/MS. Enteritidis/ U6 days-bilateral pneumonia; thrombocytopenia; secondary anemia; DM; chronic peptic ulcer disease2874/FS. Braenderup/ U5 days+gastroenterocolitis2936/FS. Infantis/ U9 days+ </td <td>13</td> <td>80/M</td> <td>S. Enteritidis/ VB</td> <td>-</td> <td>+</td> <td>prostatic carcinoma; COPD; circulatory and respiratory failure;</td>	13	80/M	S. Enteritidis/ VB	-	+	prostatic carcinoma; COPD; circulatory and respiratory failure;
1556/MS. Enteritidis/ VBat admission-non-Hodgkin lymphoma CTCL1640/FS. Enteritidis/ VB2 days-non-Hodgkin lymphoma DLBCL1731/FS. Hadar/ VB1 day-non-Hodgkin lymphoma DLBCL1864/MS. Enteritidis/ VBND+septicaemia1970/FS. Hadar/ VB4 days+food poisoning; cancer of the breast2046/FS. Enteritidis/ VB1 day-SLE2130/FS. Enteritidis/ VBND-septicaemia; HIV infection2259/FS. Enteritidis/ VBND-acute myeloblastic leukemiaClinical cases with focal infections (n = 8)2323/MS. Enteritidis/ P1 day+acute suppurative appendicitis; retrocecal abscess; gastroenterocolitis2465/MS. Enteritidis/ Pat admission-thrombocytopenia; subphrenic abscess (S. Enteritidis2465/MS. Enteritidis/ Pat admission-septicaemia; DM; myocardial infarction; subphrenic abscess; abscess of the spleen2572/MS. Enteritidis/ Pat admission-reactivity arthritis; septicaemia; coronary atheromatosis; bilateral pneumonia and bronchitis2769/MS. Enteritidis/ U6 days-bilateral pneumonia; thrombocytopenia; secondary anemia; DM; chronic peptic ulcer disease2874/FS. Braenderup/ U5 days+gastroenterocolitis2936/FS. Infantis/ U9 days+ </td <td>14</td> <td>33/F</td> <td>S. Enteritidis/ VB</td> <td>5 davs</td> <td>+</td> <td>multiple myeloma: gastrenterocolitis: renal failure</td>	14	33/F	S. Enteritidis/ VB	5 davs	+	multiple myeloma: gastrenterocolitis: renal failure
1640/FS. Enteritidis/ VB2 days-non-Hodgkin lymphoma DLBCL1731/FS. Hadar/ VB1 day-non-Hodgkin lymphoma DLBCL1864/MS. Enteritidis/ VBND+septicaemia1970/FS. Hadar/ VB4 days+food poisoning; cancer of the breast2046/FS. Enteritidis/ VB1 day-SLE2130/FS. Enteritidis/ VBND-septicaemia; HIV infection2259/FS. Enteritidis/CVC16 days-acute myeloblastic leukemia2323/MS. Enteritidis/ P1 day+acute suppurative appendicitis; retrocecal abscess; gastroenterocolitis2465/MS. Enteritidis/ Pat admission-thrombocytopenia; subphrenic abscess (S. Enteritidis2572/MS. Enteritidis/ Pat admission-septicaemia; DM; myocardial infarction; subphrenic abscess; abscess of the spleen2675/MS. Enteritidis/ BW2 days-reactivity arthritis; septicaemia; coronary atheromatosis; bilateral pneumonia and bronchitis2769/MS. Enteritidis/ U6 days-bilateral pneumonia; thrombocytopenia; sucondary anemia; DM; chronic peptic ulcer disease2874/FS. Braenderup/ U5 days+gastroenterocolitis2936/FS. Infantis/ U9 days+acute myeloblastic leukemia	15	56/M	S. Enteritidis/ VB	<u> </u>	_	
17 $31/F$ S. Hadar/ VB1 day-non-Hodgkin lymphoma DLBCL18 $64/M$ S. Enteritidis/ VBND+septicaemia19 $70/F$ S. Hadar/ VB4 days+food poisoning; cancer of the breast20 $46/F$ S. Enteritidis/ VB1 day-SLE21 $30/F$ S. Enteritidis/ VBND-septicaemia; HIV infection22 $59/F$ S. Enteritidis/CVC16 days-acute myeloblastic leukemia23 $23/M$ S. Enteritidis/ P1 day+acute suppurative appendicitis; retrocecal abscess; gastroenterocolitis24 $65/M$ S. Enteritidis/ P1 day+acute suppurative appendicitis; retrocecal abscess; (S. Enteritidis24 $65/M$ S. Enteritidis/ Pat admission-thrombocytopenia; subphrenic abscess (S. Enteritidis25 $72/M$ S. Enteritidis/ Pat admission-septicaemia; DM; myocardial infarction; subphrenic abscess; abscess of the spleen26 $75/M$ S. Enteritidis/ BW2 days-reactivity arthritis; septicaemia; coronary atheromatosis; bilateral pneumonia and bronchitis27 $69/M$ S. Enteritidis/ U6 days-bilateral pneumonia; thrombocytopenia; secondary anemia; DM; chronic peptic ulcer disease28 $74/F$ S. Braenderup/ U5 days+gastroenterocolitis29 $36/F$ S. Infantis/ U9 days+acute myeloblastic leukemia	16		S. Enteritidis/ VB	2 days	_	
18 64/M S. Enteritidis/ VB ND + septicaemia 19 70/F S. Hadar/ VB 4 days + food poisoning; cancer of the breast 20 46/F S. Enteritidis/ VB 1 day - SLE 21 30/F S. Enteritidis/ VB ND - septicaemia; HIV infection 22 59/F S. Enteritidis/ VCC 16 days - acute myeloblastic leukemia Clinical cases with focal infections (n = 8) 23 23/M S. Enteritidis/ P 1 day + acute suppurative appendicitis; retrocecal abscess; gastroenterocolitis 24 65/M S. Enteritidis/ P at admission - thrombocytopenia; subphrenic abscess (S. Enteritidis 25 72/M S. Enteritidis/ P at admission - septicaemia; DM; myocardial infarction; subphrenic abscess; abscess of the spleen 26 75/M S. Enteritidis/ BW 2 days - reactivity arthritis; septicaemia; coronary atheromatosis; bilateral pneumonia and bronchitis 27 69/M S. Enteritidis/ U 6 days - bilateral pneumonia; thrombocytopenia; secondary anemia; DM; chronic peptic ulcer disease	17	31/F	S. Hadar/ VB	-	_	
1970/FS. Hadar/ VB4 days+food poisoning; cancer of the breast2046/FS. Enteritidis/ VB1 day-SLE2130/FS. Enteritidis/ VBND-septicaemia; HIV infection2259/FS. Enteritidis/CVC16 days-acute myeloblastic leukemiaClinical cases with focal infections (n = 8)2323/MS. Enteritidis/ P1 day+acute suppurative appendicitis; retrocecal abscess; gastroenterocolitis2465/MS. Enteritidis/ Pat admission-thrombocytopenia; subphrenic abscess (S. Enteritidis2572/MS. Enteritidis/ Pat admission-septicaemia; DM; myocardial infarction; subphrenic abscess; abscess; abscess of the spleen2675/MS. Enteritidis/ BW2 days-reactivity arthritis; septicaemia; coronary atheromatosis; bilateral pneumonia and bronchitis2769/MS. Enteritidis/ U6 days-bilateral pneumonia; thrombocytopenia; secondary anemia; DM; chronic peptic ulcer disease2874/FS. Braenderup/ U5 days+gastroenterocolitis2936/FS. Infantis/ U9 days+acute myeloblastic leukemia	18	64/M	S. Enteritidis/ VB	ND	+	
2046/FS. Enteritidis/ VB1 day-SLE2130/FS. Enteritidis/ VBND-septicaemia; HIV infection2259/FS. Enteritidis/CVC16 days-acute myeloblastic leukemiaClinical cases with focal infections (n = 8)2323/MS. Enteritidis/ P1 day+acute suppurative appendicitis; retrocecal abscess; gastroenterocolitis2465/MS. Enteritidis/ Pat admission-thrombocytopenia; subphrenic abscess (S. Enteritidis2465/MS. Enteritidis/ Pat admission-septicaemia; DM; myocardial infarction; subphrenic abscess; abscess; abscess of the spleen2572/MS. Enteritidis/ Pat admission-septicaemia; DM; myocardial infarction; subphrenic abscess; abscess of the spleen2675/MS. Enteritidis/ U6 days-reactivity arthritis; septicaemia; coronary atheromatosis; bilateral pneumonia and bronchitis2769/MS. Enteritidis/ U6 days-bilateral pneumonia; thrombocytopenia; secondary anemia; DM; chronic peptic ulcer disease2874/FS. Braenderup/ U5 days+gastroenterocolitis2936/FS. Infantis/ U9 days+acute myeloblastic leukemia	19	70/F	S. Hadar/ VB	4 days	+	*
2130/FS. Enteritidis/ VBND-septicaemia; HIV infection2259/FS. Enteritidis/CVC16 days-acute myeloblastic leukemiaClinical cases with focal infections (n = 8)2323/MS. Enteritidis/ P1 day+acute suppurative appendicitis; retrocecal abscess; gastroenterocolitis2465/MS. Enteritidis/ Pat admission-thrombocytopenia; subphrenic abscess (S. Enteritidis2465/MS. Enteritidis/ Pat admission-septicaemia; DM; myocardial infarction; subphrenic abscess; abscess; asscess; asscess; asscess; asscess; asscess; asscess; abscess of the spleen2675/MS. Enteritidis/ BW2 days-reactivity arthritis; septicaemia; coronary atheromatosis; bilateral pneumonia and bronchitis2769/MS. Enteritidis/ U6 days-bilateral pneumonia; thrombocytopenia; secondary anemia; DM; chronic peptic ulcer disease2874/FS. Braenderup/ U5 days+gastroenterocolitis2936/FS. Infantis/ U9 days+acute myeloblastic leukemia	20	46/F	S. Enteritidis/ VB	1 day	_	
22 59/F S. Enteritidis/CVC 16 days - acute myeloblastic leukemia Clinical cases with focal infections (n = 8) 23 23/M S. Enteritidis/P 1 day + acute suppurative appendicitis; retrocecal abscess; gastroenterocolitis 24 65/M S. Enteritidis/P at admission - thrombocytopenia; subphrenic abscess (S. Enteritidis and P. aeruginosa etiology); arterial hypertension; steroid diabetes 25 72/M S. Enteritidis/P at admission - septicaemia; DM; myocardial infarction; subphrenic abscess; abscess of the spleen 26 75/M S. Enteritidis/ BW 2 days - reactivity arthritis; septicaemia; coronary atheromatosis; bilateral pneumonia and bronchitis 27 69/M S. Enteritidis/ U 6 days - bilateral pneumonia; thrombocytopenia; secondary anemia; DM; chronic peptic ulcer disease 28 74/F S. Braenderup/ U 5 days + gastroenterocolitis 29 36/F S. Infantis/ U 9 days + acute myeloblastic leukemia	21	30/F	S. Enteritidis/ VB		_	septicaemia; HIV infection
Clinical cases with focal infections (n = 8)2323/MS. Enteritidis/ P1 day+acute suppurative appendicitis; retrocecal abscess; gastroenterocolitis2465/MS. Enteritidis/ Pat admission-thrombocytopenia; subphrenic abscess (S. Enteritidis2572/MS. Enteritidis/ Pat admission-septicaemia; DM; myocardial infarction; subphrenic abscess; abscess of the spleen2675/MS. Enteritidis/ BW2 days-reactivity arthritis; septicaemia; coronary atheromatosis; bilateral pneumonia and bronchitis2769/MS. Enteritidis/ U6 days-bilateral pneumonia; thrombocytopenia; secondary anemia; DM; chronic peptic ulcer disease2874/FS. Braenderup/ U5 days+gastroenterocolitis2936/FS. Infantis/ U9 days+acute myeloblastic leukemia	22	59/F	S. Enteritidis/CVC	16 days	_	
2465/MS. Enteritidis/ Pat admission-thrombocytopenia; subphrenic abscess (S. Enteritidis and P. aeruginosa etiology); arterial hypertension; steroid diabetes2572/MS. Enteritidis/ Pat admission-septicaemia; DM; myocardial infarction; subphrenic abscess; abscess of the spleen2675/MS. Enteritidis/ BW2 days-reactivity arthritis; septicaemia; coronary atheromatosis; bilateral pneumonia and bronchitis2769/MS. Enteritidis/ U6 days-bilateral pneumonia; thrombocytopenia; secondary anemia; DM; chronic peptic ulcer disease2874/FS. Braenderup/ U5 days+gastroenterocolitis2936/FS. Infantis/ U9 days+acute myeloblastic leukemia					inical cases wit	
Image: second	23	23/M	S. Enteritidis/ P	1 day	+	acute suppurative appendicitis; retrocecal abscess; gastroenterocolitis
2572/MS. Enteritidis/ Pat admission-septicaemia; DM; myocardial infarction; subphrenic abscess; abscess of the spleen2675/MS. Enteritidis/ BW2 days-reactivity arthritis; septicaemia; coronary atheromatosis; bilateral pneumonia and bronchitis2769/MS. Enteritidis/ U6 days-bilateral pneumonia; thrombocytopenia; secondary anemia; DM; chronic peptic ulcer disease2874/FS. Braenderup/ U5 days+gastroenterocolitis2936/FS. Infantis/ U9 days+acute myeloblastic leukemia	24	65/M	S. Enteritidis/ P	at admission	_	
Image: secondary and second	25	72/M	S. Enteritidis/ P	at admission	_	septicaemia; DM; myocardial infarction; subphrenic abscess;
28 74/F S. Braenderup/ U 5 days + gastroenterocolitis 29 36/F S. Infantis/ U 9 days + acute myeloblastic leukemia	26	75/M	S. Enteritidis/ BW	2 days	_	reactivity arthritis; septicaemia; coronary atheromatosis;
28 74/F S. Braenderup/ U 5 days + gastroenterocolitis 29 36/F S. Infantis/ U 9 days + acute myeloblastic leukemia	27	69/M	S. Enteritidis/ U	6 days	_	bilateral pneumonia; thrombocytopenia; secondary anemia; DM;
29 36/F S. Infantis/ U 9 days + acute myeloblastic leukemia	28	74/F	S. Braenderup/ U	5 days	+	
	29	36/F		-	+	
	30	67/M	S. Enteritidis/ U	-	_	chronic renal failure; glomerulonephritis in the course of vasculitis

^{a)} Number of hospitalization day(s) until extraintestinal salmonella infection appearance; NTS – non-typhoid salmonella; COPD – chronic obstructive pulmonary disease; DM – diabetes mellitus; SLE – systemic lupus erythematosus; NT – not tested; ND – data not available; (+) – present; (-) – absent; F – female; M – male; VB – venous blood; CVC – central venous catheter; U – urine; P – pus; BW – bronchial washings

bronchial washings samples (3.4%). Table II shows the demographic and clinical data in-patients who had bacteraemia or other extraintestinal non-bacteraemic infections, including those patients with and without gastrenterocolitis. The average age of salmonella bacteraemia patients was 42 (30–80 year), but more than 50% of them were older than 60. In nearly more than 50% of patients there was at least one risk factor responsible to dissemination. Eight patients had a localized salmonella infections, including three who had undergone successful surgery. The overall risk factors for non-typhoid salmonella infection with varied manifestations are summarized in Table III. Out of 30 patients with either bacteraemia or focal salmonella infections, 30% had hematological malignancies, 57% had immunodeficiency, 27% had chronic liver, pulmonary and renal diseases, 10% had solid organ cancers, diabetes mellitus or organ abscesses, 7% had hyper-

Table III Background and manifestations of non-typhoid salmonella with extraintestinal infections

Background and manifestation	Clinical cases (cases numbers) ^{a)}			
Malignancy	Solid organ cancers (3) [Prostatic carcinoma-1, lung neoplastic tumor-1, breast-1 ^b]; Hematological malignancy (9) [Neoplasm dissemination of lymphatic system (1), multiple myeloma (2), chronic lymphatic leukaemia (1), acute myeloblastic leukemia (2), non-Hodgkin lymphoma (3)]			
Immunodeficiency ^{c)}	HIV infection (1), neutropenia (1), use of chemotherapeutic agents (7), use of immuno- suppressive agents (2), exclusive corticosteroid use (9), agranulocytosis (3); SLE (1)			
Other underlying medical diseases	Gastrointestinal disorders (9), chronic renal failure (3), septicaemia (9), COPD (2), posthe- patitic cirrhosis (1), subphrenic abscess (2) ^{d)} , abscess of the spleen (1), retrocecal abscess (1), aplastic anemia (1), acute suppurative appendicitis (1), DM, including steroid diabetes (3); bilateral pneumonia and bronchitis (2), cardiovascular diseases mainly encompassing hyper- tension (2) and heart failure (2), thrombocytopenia (2); epilepsy (1), skeletal disorder (1)			

^{a)} Description of abbreviations as in the legend to Table II; ^{b)} Patient had mastectomy; ^{c)}Immune dysfunction excluding malignancies;
^{d)} Patient had subphrenic abscess evacuation, postoperative drainage, recurrent laparotomy with body, and tail of the pancreas removal due to acute pancreatic necrosis

Case	Gen- der	Age (years)	Co morbidity	Predisposing intervention	NTS Isolate/Source	No. of day(s) ^{b)}	Comment(s)/other new diagnoses
1	F	40	Non-Hodgkin lymphoma DLBCL	Chemotherapy; exclusive steroid use	S. Enteritidis/VB	2 day illness	Central venous catheter
2	М	75	Reactivity arthritis; coronary atheromatosis; bilateral pneumonia; bilateral bronchitis	Parenteral nutrition	S. Enteritidis/BW	2 day illness	Patient after gastrectomy at 1982, and cholecystectomy; bilateral inflammatory infil- tration in lungs; lung neo- plastic tumo(u)r suspicion; treated due to tuberculosis; respiratory failure; hipox(a)emia; instant circulatory arrest
3	М	60	Renal transplantation	Immunosuppression after renal transplanta- tion (8 years)	S. Enteritidis/VB	at admission	Death due to overwhelming sepsis;
4	F	33	Multiple myeloma	Chemotherapy	S. Enteritidis/VB	5 day illness	Gastroenterocolitis; renal failure

Table IV Characteristics and presentations of fatal non-typhoid salmonella bacteraemia $(n = 4)^{a}$

^{a)} Description of abbreviations as in the legend to Table II; ^{b)}Number of hospitalization days until extraintestinal salmonella infection appearance

tension and 1 patient had reactivity arthritis. Four of 30 patients (13%) died (Table IV).

Most isolates remained highly susceptible to all 5 antimicrobial agents examined, with the exception of four isolates, including *S*. Enteritidis (resistant to ampicillin and trimethroprim-sulfamethoxazole); *S*. Hadar (resistant to ampicillin and ciprofloxacin); *S*. Hadar (resistant to ciprofloxacin) and *S*. Braenderup (resistant to ampicillin and ciprofloxacin). None of the tested isolates demonstrated an ESBL phenotype.

Discussion

Enteric fever is imported to developed countries while non-typhoid salmonella infections occur globally. It is, however, of note that in Poland number of bacterial foot borne infections and intoxications remain high - 19 870 cases (52.0 per 100 000), and 79.6% of them were caused by Salmonella (Zieliński and Czarkowski, 2006). Approximately 5% of gastroenteritis develop bacteraemia, and <1% have focal infections such as osteomyelitis, soft tissue infection, urinary tract infection or endocarditis (Miller and Pegues, 2000). Ramos et al. (1996) retrospectively reviewed the charts of 183 patients with extraintestinal salmonellosis, and proposed classification of these patients into four groups, including primary bacteraemia, enteritis-associated bacteraemia (secondary bacteraemia), digestive focal infection, and non-digestive focal infection. The greatest risk of acquiring focal infections is associated with the existence of underlying illness or immunodepression (Ruiz et al., 2000). In our study we presented thirty cases of severe diseases complicated by

non-typhoid salmonella infections that occurred over a period of 7 years. Blood cultures were positive in twenty two (73%) cases, including twenty with S. Enteritidis, and only two with S. Hadar. Nearly half of these sepsis cases had underlying diseases: hematological malignances, solid organ cancers, liver disease, HIV infection, diabetes mellitus, and chronic heart and kidney diseases. In our patients with non-typhoid salmonellosis, the major patients risk factors for bacteraemia were certain immunocompromised conditions. Brown and Eykyn (2000) reported that in patients presenting with non-typhoid salmonella bacteraemia in the absence of gastroenteritis, underlying immunodeficiency should be excluded first. These findings point to the importance of the immune system in the defense against salmonella infection. Five years later, Hsu and Lin (2005) presented clinical data that showed that adult patients (≥ 18 years) with nontyphoid salmonellosis who had bacteraemia were older, and had more underlying diseases of liver cirrhosis, systemic lupus erythematosus, immunodeficiency, and solid organ cancers than patients who had gastroenteritis alone. Moreover, the same authors using log-logistic regression determined that the independent positive predictors of bloodstream infection in adult were SLE, liver cirrhosis, HIV infection, and solid organ cancers. They also confirmed that immunodeficiency predisposed patients to acquire non-typhoid salmonella bacteraemia. In other study, Ramos et al. (1996) revealed the differences between patients with primary and enteritis-associated bacteraemia. The first mentioned one characterized higher severe immunosuppression, and mortality, but lower community acquisition. In the present study nearly more than half of our in-patients with primary bacteraemia had severe immunosuppression due to hematological malignances, systemic lupus erythematosus, HIV infection, and renal transplantation.

We also determined the incidence four cases of non-typhoid salmonella bacteraemia, including three cases of chronic renal failure, and one case of renal transplant recipient followed by our Nephrology Unit. Dhar *et al.* (1991) reported the results of an analysis of 20 cases of NTS infection that occurred over a period of 10 years in 592 renal transplant recipients. This pathology usually occurs when immunosuppression is high – early in the post-transplant period or after anti-rejection therapy. They suggested that despite prolonged antibiotic therapy, relapses occur commonly causing significant morbidity, occasional graft loss and even death.

Bacterial infection is well-described complication of liver cirrhosis, and is a major cause of death (Barrio *et al.*, 1999; Brann, 2001). In this study posthepatitic liver cirrhosis due to virus hepatitis C infection was associated with high incidence of *S*. Enteritidis bloodstream infection. This strain was collected from 72-year old man with virus hepatitis C infection. From the results of a study by Brann (2001), non-typhoid salmonella was an infrequent cause of bacteraemia in cirrhotic patients. The specific risk factors for infection in cirrhotic patients included low serum albumin, gastrointestinal bleeding, intensive care unit admission for any cause, and therapeutic endoscopy.

In non-typhoid salmonellosis, gastroenteritis is the usual presentation and bacteraemia is less common, suggesting invasiveness and severity (Habib, 2004). In our study, the recorded mortality was 4/30 (13%). Three patients had immunosuppressive states, and interventions while the fourth patient were older with more co-morbid diseases, and previous surgical procedures. A recent Danish study showed that increasing age, and increasing levels of co morbidity were independently associated with an mortality, whereas none of the clinical and laboratory variables studied were strong independent prognostic factors (Gradel et al., 2006). Habib (2004) noticed that clinicians need to treat elderly patients and to consider preemptive therapy or even chemoprophylaxis particularly in patients with prior salmonella infection who are likely to develop severe immunosuppression, especially if there is associated lymphopenia.

Another patients had *Salmonella* in pus, bronchial washing, and urine. Among the extraintestinal manifestations of salmonellosis, infection of the urinary tract is infrequent (Gagnon et al., 2007). It occurs when there is a predisposition, such as occult urological problem or immunosuppression. Our patients were predisposed to this rare complication of salmonellosis because they were under corticosteroid therapy or chemotherapy, agranulocytosis, and chronic renal failure. With immune dysfunction, infections often present without gastroenteritis (Brown and Eykyn, 2000) in unusual locations, as seen here with S. Enteritidis isolated from subphrenic and spleen abscesses. These strains were collected from 72-year old man with diabetes mellitus (DM) and from 65-year old man with arterial hypertension, steroid diabetes and thrombocytopenia. These patients were successfully treated with drainage of the abscesses. Recently, Yamagata et al. (2006) have reported a rare case of Salmonella submandibular abscess in 59-year old patient with DM, chronic hepatitis and liver cirrhosis. The authors speculate that an immunocompromised condition can be a critical predisposing factor for Salmonella abscesses with different location. Another patient had pulmonary disorder, the presence of comorbid diseases and old age. He was bronchial washing culture positive for S. Enteritidis. In a Danish study published in 2007, the acquisition and pathogenesis of more severe NTS infections in debilitated patients was more related to endogenous host characteristic than in healthier patients in whom exogenous factors may be more crucial (Gradel *et al.*, 2007). We revealed that the incidence rate (mean 0.30/1000 hospital admission/year) increased steadily from 0.19/1000 hospital admission in the 2000 year to 0.32/1000 hospital admission in the 2006 year. The trend of gradually increased annual case numbers or incidence rate has also been reported previously (Gradel *et al.*, 2006; Jean *et al.*, 2006).

We reviewed the susceptibility pattern of Salmo*nella* serotypes to a standard battery of five antibiotics in patients with extraintestinal non-typhoid salmonella manifestations at our Hospital in-patients Departments. The results of this study show that multidrug resistance, especially fluoroquinolone resistance, does not represent a serious problem among Salmonella isolates collected from the University Hospital medical center as monitored over a period of 7 years. From 22 bloodstream samples collected, two S. Hadar isolates were resistance to ciprofloxacin, and one was resistant to ampicillin. These strains were collected from 31-year old woman with non-Hodgkin lymphoma, and from 70-year old woman who had previous history of mastectomy. In conclusion, given this presentation, clinicians need to have a high index of suspicion and to consider preemptive therapy, especially in elderly patients who are likely to develop severe immunosuppression following interventions.

Acknowlegments

This research was supported by grant No. 501/NKL/291/L of the Jagiellonian University Medical College.

Literature

Barrio J., A. Castiella and M.A. Von Wichman. 1999. Spontaneous bacteremia due to *Salmonella* Hadar in liver cirrhosis with transjugular intrahepatic portosystemic shunt. *Gastroenterol. Hepatol*. 22: 79–81.

Brann O.S. 2001. Infectious complications of cirrhosis. *Curr. Gastroenterol. Rep.* 3: 285–292.

Brown M. and S.J. Eykyn. 2000. Non-typhoidal Salmonella bacteraemia without gastroenteritis: a marker of underlying immunosuppression. Review of case sat St. Thomas'Hospital 1970–1999. *J. Infect.* 41: 256–259.

Day L.J., Q.J. Qayyum and C.A. Kauffman. 2002. Salmonella prosthetic joint septic arthritis. *Clin. Microbiol. Infect.* 8: 427–430. Dhar J.M., A.A. al-Khader and M. al-Sulaiman. 1991. Nontyphoid Salmonella in renal transplant recipients: a report of twenty cases and review of the literature. *Q. J. Med.* 78: 235–250. Gagnon J., R. Labbe and B. Laroche. 2007. Salmonella urinary tract infection: a vascular emergency. *Can. J. Surg.* 50: 221–222. Glaser J.B., L. Morton-Kute and S.R. Berger. 1985. Recurrent *Salmonella typhimurium* bacteremia associated with the acquired immunodeficiency syndrome. *Ann. Intern. Med.* 102: 189–193.

Gordon M.A., A.L. Walsh and M. Chaponda. 2001. Bacteraemia and mortality among adult medical admissions in Malawi - predominance of non-typhi salmonellae and *Streptococcus* pneumoniae. J. Infect. 42: 44–49.

Gönen C., A. Topeli and Y.S. Cetinkaya. 2004. Prosthetic valve endocarditis caused by *Salmonella enteritidis*. *Scand. J. Infect. Dis.* 36: 72–75.

Gradel K.O., C. Dethlefsen and H.C. Schønheyder. 2007. Severity of infection and seasonal variation of non-typhoid *Salmonella* occurrence in humans. *Epidemiol. Infect.* 135: 93–99.

Gradel K.O., H.C. Schønheyder and L. Pedersen. 2006. Incidence and prognosis of nontyphoid *Salmonella* bacteraemia in Denmark: a 10-year county-based follow-up study. *Eur. J. Clin. Microbiol. Infect. Dis.* 25: 151–158.

Habib A.G. 2004. A clinical audit of presentation and outcome of Salmonella septicaemia. *Ann. Acad. Med. Singapore* 33: 749–753. Hohmann E.L. 2001. Nontyphoidal salmonellosis. *Clin. Infect. Dis.* 32: 263–269.

Hsu R.B. and F.Y. Lin. 2005. Risk factors for bacteraemia and endovascular infection due to non-typhoid *salmonella*: a reappraisal. *Q. J. Med.* 98: 821–827.

Hsu R.B., Y.G. Tsay and R.J. Chen. 2003. Risk factors for primary bacteremia and endovascular infection in patients without acquired immunodeficiency syndrome who have nontyphoid salmonellosis. *Clin. Infect. Dis.* 36: 829–834.

Jariel V., M.H. Nicolas and G. Fournier. 1988. Extended broadspectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in *Enterobacteriaceae*: hospital prevalence and susceptibility patterns. *Rev. Infect. Dis.* 10: 867–878.

Jean S.S., J.Y. Wang and P.R. Hsueh. 2006. Bacteremia caused by *Salmonella enterica* serotype Choleraesuis in Taiwan. J. Microbiol. Immunol. Infect. 39: 358–365.

Miller S.L. and D.A. Pegues. 2000. Salmonella species, including Salmonella typhi, p. 2344–2363. In: Mandell G.L. J.E. Bennett and R. Dolin (ed.), Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 5th ed. Churchill Livingstone, Philadelphia, Pa.

Minami K., T. Yanagawa and M. Okuda. 2004. Cerebrospinal fluid cytokines in Salmonella *Urbana* encephalopathy. *Tohoku. J. Exp. Med.* 203: 129–132.

National Committee for Clinical Laboratory Standards. 2003a. Methods for Dilution Susceptibility Tests for Bacteria That Grow Aerobically; Approved standard – Sixth Edition: M7-A6. NCCLS, Villanova, PA.

Ohl M.E. and S.I. Miller. 2001. Salmonella: a model for bacterial pathogenesis. *Annu. Rev. Med.* 52: 259–274.

Pagano L., E. Tacconelli and M. Tumbarello. 1997. Bacteremia in patients with hematological malignancies. Analysis of risk factors, etiological agents and prognostic indicators. *Haematologica* 82: 415–419.

Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement. CLSI M100-S17, Vol. 27, No.1, 2007.

Ramos J.M., P. Garcia-Corbeira and J.M. Aguado. 1996. Classifying extraintestinal non-typhoid Salmonella infections. *Q. J. Med.* 89: 123–126.

Ruiz M., J.C. Rodriguez and M. Elia. 2000. Extraintestinal infections caused by non-typhi Salmonella serotypes. 9-yrs' experience. *Enferm. Infect. Microbiol. Clin.* 18: 219–222.

Yamagata K. M. Takeda and K. Onizawa. 2006. Submandibular abscess caused by Salmonella. *Int. J. Oral. Maxillofacial. Surgery* 35: 969–971.

Zieliński A. and M.P. Czarkowski. 2006. Infectious diseases in Poland in 2004 (in Polish). *Przegl. Epidemiol.* 60: 373–382.